IMS - Integrated Management Solutions
to improve healthcareIMS – Integrated Management Solutions assists healthcare providers, helping to improve patient outcome(s) through treatment improvement, care provision and healthcare access.
IMS provides cutting edge information, technology and management solutions to tackle clinical, scientific and commercial results.
Exploiting Innovation, IMS kicks healthcare forward
For almost 20 years IMS – long known in Italy as “Istituto di Management Sanitario” – provided services of Healthcare Management, Support to Scientific Research and Information Technology in health bringing together multidisciplinary professional expertise matured in the last thirty years in different fields.
IMS partners are professionals with different background in research, healthcare and management, who have been working in prestigious Italian and international healthcare institutions.
IMS is active exclusively in the healthcare sector, in the fields of Consulting, Management of Research Projects, Clinical Studies and Clinical Trials.
Major IMS customers are Local and Regional Healthcare Services, Universities and Research Centers, Public and Private Institutions active in specific and/or specialized clinical/healthcare sectors, from social-assistance to research.
IMS manages any specific issue emerging during the projects with a strategic and productive approach, that enables to reach the results with the best reliability and appropriateness possible in the different contexts.
Latest projects
PAIN ReLife
Focuses on the creation of a dynamic and integrated ecosystem based on big data technologies aimed at the continuity of care for patients with chronic pain. This ecosystem involves the entire health supply chain to grant personalized therapy, monitoring and support to the decision-making process.
CardiOCare
An Interdisciplinary Approach for the Management of the Elderly Multimorbid Patient with Breast Cancer Therapy Induced Cardiac Toxicity.
iPS Light
The project aims at the technological development of human stem cells, re-programmed iPSC (induced pluripotent stem cell) from patients diagnosed with neurodegenerative diseases, applicable to industrial pharmaceutical research in combination with leading edge high-content and high-throughput screening (HCS, HTS).
